[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-337252-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-337252-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","exploring-bevacizumabs-role-in-gynecological-cancers-an-up-to-date-narrative-review-focusing-on-ovarian-cancer","Exploring Bevacizumab's Role in Gynecological Cancers: An Up-to-Date Narrative Review Focusing on Ovarian Cancer","","Gynecological cancers, including ovarian, endometrial, breast, and cervical cancers, have risen in incidence worldwide, with ovarian cancer remaining highly lethal due to late-stage diagnosis and biological heterogeneity. This narrative review evaluates literature findings on bevacizumab, an anti-angiogenic monoclonal antibody targeting tumor angiogenesis pathways, emphasizing ovarian cancer. It summarizes efficacy as monotherapy and in combination regimens, and reviews safety, potential toxicity, and future research needs across cancer subtypes and molecular factors.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/exploring-bevacizumabs-role-in-gynecological-cancers-an-up-to-date-narrative-review-focusing-on-ovarian-cancer/337252/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/exploring-bevacizumabs-role-in-gynecological-cancers-an-up-to-date-narrative-review-focusing-on-ovarian-cancer/337252.png","ImageObject",300,407,{"name":42,"@type":43},"Valentina","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is bevacizumab and why is it relevant to gynecological cancers?","Question",{"text":63,"@type":64},"Bevacizumab is an anti-angiogenic monoclonal antibody that binds factors essential for tumor angiogenesis, including VEGF-A. The review positions it as an important therapeutic approach for gynecological cancers.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does the review describe bevacizumab’s effectiveness?",{"text":68,"@type":64},"It highlights evidence supporting bevacizumab as a key agent, particularly in ovarian cancer, with efficacy reported for both monotherapy and combination with other treatments. The review emphasizes careful patient dosing.",{"name":70,"@type":61,"acceptedAnswer":71},"What future research directions are suggested?",{"text":72,"@type":64},"The review calls for further investigation of bevacizumab use in other gynecological cancers, in specific cancer subtypes, and in relation to factors that may affect efficiency such as molecular mutations or polymorphisms.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},337252,1790117550,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":113},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","DOI: 10.5455/msm.2024.36.268-279  \nReceived: Nov 12 2024; Accepted: Dec 28, 2024  \n© 2024 Elias Liolis, Francesk Mulita, Angelos Koutras, Thomas Makatsoris, Gregory Sivolapenko  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ([http://creativecommons.org/licenses/](http://creativecommons.org/licenses/)  \n[by-nc/4.0/](by-nc/4.0/)) [which permits unrestricted non-commercial use](which permits unrestricted non-commercial use), [distribution](distribution), [and reproduction in any medium](and reproduction in any medium), [provided the original work is properly cited](provided the original work is properly cited).  \nCROSS-SECTIONAL STUDY Mater Sociomed. 2024; 36(4): 268-279  \n1Department of Oncology, General University Hospital of Patras, Greece  \n2Department of Surgery, General University Hospital of Patras, Greece  \n3Laboratory of Pharmacokinetics, Department of Pharmacy, University of Patras, Patras, Greece  \nCorresponding author: Francesk Mulita. Department of Surgery, General University Hospital of Patras, Greece. Tel.:  \nE-mail: oknarfmulita@ [hotmail.com. ORCID](hotmail.com. ORCID)ID: [http](http)(([www.orcid](www.orcid). org/0000-0003-2865- 0446  \nExploring Bevacizumab's Role in Gynecological Cancers: An Up-toDate Narrative Review Focusing on Ovarian Cancer  \nElias Liolis1, Francesk Mulita2, Angelos Koutras1, Thomas Makatsoris1, Gregory Sivolapenko3  \nABSTRACT  \nBackground: The Gynecological cancers, including ovarian cancer, endometrial cancer, breast cancer, and cervical cancer, have increased in frequency lately and it is estimated that one million cases are diagnosed every year worldwide. Bevacizumab is considered one of the first anti-angiogenic therapies as it is a monoclonal antibody binding to factors essential for tumor angiogenesis. Objective: This paper aims to review the most important findings of the literature that highlight the role of bevacizumab in gynecological cancers with a special emphasis on ovarian cance. Methods:  \nFor this narrative review, an extensive literature search was conducted using Pubmed and Web of Science to collect the most important papers investigating the role of bevacizumab in gynecological cancers, such as cervical cancer, breast cancer, endometrial cancer, and ovarian cancer. Results: Results regarding its use as monotherapy or in combination with chemotherapy and other regimens will be presented. A particular focus will be held also on findings regarding its safety and potential toxicity as well as its effectiveness. Conclusion: Bevacizumab is a key agent in the treatment of all gynecological cancers especially in the case of ovarian cancer as there is extensive evidence of its efficacy as monotherapy as well as in combination with other agents, with careful patient dosing. However, future research should focus also on the investigation of its use in other gynecological cancers. Furthermore, more investigation is required regarding its use in specific subtypes of cancer, associated e.g.  \nwith specific mutations or polymorphisms, or on factors that can affect its efficiency, such asthe BMI as indicated by some studies. Finally, it should be noted that though this is not a systematic review of the literature, it highlights the more important findings paving the road for future research and guidelines about the appropriate use of bevacizumab ingynecological cancers.  \nKeywords: Gynecological cancers, bevacizumab, ovarian cancer, chemotherapy.  \n1. BACKGROUND  \nGynecological cancers, including ovarian cancer, endometrial cancer, breast cancer, and cervical cancer, have increased in frequency lately and it is estimated that one million cases are diagnosed every year worldwide (1) . More specifically, ovarian cancer is one of the most important cancers for women as itis considered the fifth leading cause of cancer-related deaths in the USA (2) and the most fatal among gynecological cancers (3, 4). Moreover, the ter","cbCaifCRx2V8xQJR","https://ap.wps.com/l/cbCaifCRx2V8xQJR","pdf",270106,"English","# Abstract\n## Background\n## Objective\n## Methods\n## Results\n## Conclusion\n# Keywords\n# Background","[{\"question\":\"What is bevacizumab and why is it relevant to gynecological cancers?\",\"answer\":\"Bevacizumab is an anti-angiogenic monoclonal antibody that binds factors essential for tumor angiogenesis, including VEGF-A. The review positions it as an important therapeutic approach for gynecological cancers.\"},{\"question\":\"How does the review describe bevacizumab’s effectiveness?\",\"answer\":\"It highlights evidence supporting bevacizumab as a key agent, particularly in ovarian cancer, with efficacy reported for both monotherapy and combination with other treatments. The review emphasizes careful patient dosing.\"},{\"question\":\"What future research directions are suggested?\",\"answer\":\"The review calls for further investigation of bevacizumab use in other gynecological cancers, in specific cancer subtypes, and in relation to factors that may affect efficiency such as molecular mutations or polymorphisms.\"}]","Exploring Bevacizumab's Role in Gynecological Cancers: An Up-to-Date Narrative Review Focusing on Ovarian Cancer | PDF",1790018354]